UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 20, 2004
AMYLIN PHARMACEUTICALS, INC. |
(Exact name of registrant as specified in its charter) |
| | | | |
Delaware | | 0-19700 | | 33-0266089 |
(State or other jurisdiction
of incorporation) | | (Commission
File Number) | | (IRS Employer
Identification No.) |
| | | | |
9360 Towne Centre Drive, Suite 110
San Diego, California | | 92121 |
(Address of principal executive offices) | | (Zip Code) |
Registrant’s telephone number, including area code: (858) 552-2200
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events.
On September 20, 2004, Amylin Pharmaceuticals, Inc. (the “Company”) issued a press release announcing the submission of the Complete Response to the second approvable letter for SYMLIN® (pramlintide acetate), the Company’s drug candidate under review by the U.S. Food and Drug Administration for the treatment of people with type 1 and insulin-using type 2 diabetes. A copy of this press release is attached as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits.
(c) Exhibits
99.1 | | Press Release issued by the Company on September 20, 2004. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| AMYLIN PHARMACEUTICALS, INC. |
| |
Dated: September 20, 2004 | By: | /S/ LLOYD A. ROWLAND | |
| | Lloyd A. Rowland |
| | Vice President, Legal, Secretary and |
| | General Counsel |
| | | | | |
2
Exhibit Index
Exhibit No. | | |
| | |
99.1 | | Press Release issued by the Company on September 20, 2004. |
3
